Inhibition of ligand-independent constitutive activation of the met oncogenic receptor by the engineered chemically-modified antibody DN30

An awesome number of experimental and clinical evidences indicate that constitutive activation of the Met oncogenic receptor plays a critical role in the progression of cancer toward metastasis and/or resistance to targeted therapies. While mutations are rare, the common mechanism of Met activation is overexpression, either by gene amplification (‘addiction’) or transcriptional activation (‘expedience’). In the first instance ligand-independent kinase activation plays a major role in sustaining the transformed phenotype.

Source: Molecular Oncology - June 4, 2015 Category: Cancer & Oncology Authors: Elisa Vigna, Cristina Chiriaco, Simona Cignetto, Lara Fontani, Cristina Basilico, Fiorella Petronzelli, Paolo M. Comoglio Source Type: research